96 related articles for article (PubMed ID: 25064638)
1. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
2. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT.
Taylor NJ; Mitra N; Qian L; Avril MF; Bishop DT; Bressac-de Paillerets B; Bruno W; Calista D; Cuellar F; Cust AE; Demenais F; Elder DE; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Gruis NA; Hansson J; Harland M; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Mann GJ; Nagore E; Olsson H; Palmer JM; Perić B; Pjanova D; Pritchard AL; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Yang XR; Newton-Bishop JA; Kanetsky PA;
J Am Acad Dermatol; 2019 Aug; 81(2):386-394. PubMed ID: 30731170
[TBL] [Abstract][Full Text] [Related]
3. Histologic features of melanoma associated with CDKN2A genotype.
Sargen MR; Kanetsky PA; Newton-Bishop J; Hayward NK; Mann GJ; Gruis NA; Tucker MA; Goldstein AM; Bianchi-Scarra G; Puig S; Elder DE
J Am Acad Dermatol; 2015 Mar; 72(3):496-507.e7. PubMed ID: 25592620
[TBL] [Abstract][Full Text] [Related]
4. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations.
Helgadottir H; Olsson H; Tucker MA; Yang XR; Höiom V; Goldstein AM
Genet Med; 2018 Sep; 20(9):1087-1090. PubMed ID: 29215650
[TBL] [Abstract][Full Text] [Related]
5. Familial features affecting the melanoma risk in
Helgadottir H; Schultz K; Lapins J; Höiom V
Acta Oncol; 2023 Dec; 62(12):1967-1972. PubMed ID: 37801364
[No Abstract] [Full Text] [Related]
6. High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: A multicentre cohort from the MelaNostrum Consortium.
Pellegrini C; Cardelli L; Ghiorzo P; Pastorino L; Potrony M; García-Casado Z; Elefanti L; Stefanaki I; Mastrangelo M; Necozione S; Aguilera P; Rodríguez-Hernández A; Di Nardo L; Rocco T; Del Regno L; Badenas C; Carrera C; Malvehy J; Requena C; Bañuls J; Stratigos AJ; Peris K; Menin C; Calista D; Nagore E; Puig S; Landi MT; Fargnoli MC
J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2498-2508. PubMed ID: 37611275
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families.
Taylor NJ; Handorf EA; Mitra N; Avril MF; Azizi E; Bergman W; Bianchi-Scarrà G; Bishop DT; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Friedman E; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Hansson J; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer J; Perić B; Pjanova D; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA;
J Invest Dermatol; 2016 May; 136(5):1066-1069. PubMed ID: 26827760
[No Abstract] [Full Text] [Related]
8. Immunophenotypic p14 and p16 correlations with CDKN2A mutations in primary multiple and familial melanoma: An observational study.
Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Orășanu CI; Boşoteanu M
Medicine (Baltimore); 2023 Dec; 102(51):e36756. PubMed ID: 38134090
[TBL] [Abstract][Full Text] [Related]
9. Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome.
Sargen MR; Kim J; Potjer TP; Velthuizen ME; Martir-Negron AE; Odia Y; Helgadottir H; Hatton JN; Haley JS; Thone G; Widemann BC; Gross AM; Yohe ME; Kaplan RN; Shern JF; Sundby RT; Astiazaran-Symonds E; Yang XR; Carey DJ; Tucker MA; Stewart DR; Goldstein AM
JAMA Dermatol; 2023 Oct; 159(10):1112-1118. PubMed ID: 37585199
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result.
Leof ER; Zhu X; Rabe KG; McCormick JB; Petersen GM; Radecki Breitkopf C
Genet Med; 2019 Nov; 21(11):2468-2477. PubMed ID: 30992552
[TBL] [Abstract][Full Text] [Related]
11. Genetic testing for familial melanoma.
Primiero CA; Maas EJ; Wallingford CK; Soyer HP; McInerney-Leo AM
Ital J Dermatol Venerol; 2024 Feb; 159(1):34-42. PubMed ID: 38287743
[TBL] [Abstract][Full Text] [Related]
12. Surgical outcomes after pancreatic surgery in patients with a germline CDKN2A/p16 pathogenic variant under surveillance.
Onnekink AM; Michiels N; Klatte DCF; Oldenburg L; Mieog JSD; Vahrmeijer AL; van Hooft JE; van Leerdam ME; Bonsing BA
Br J Surg; 2024 Jan; 111(1):. PubMed ID: 38156443
[No Abstract] [Full Text] [Related]
13. CD8-Lymphocytic Phenotype Significance in Primary Multiple and Familial Melanoma with Various CDKN2A Mutational Status.
Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Bălțătescu GI; Orășanu CI; Boşoteanu M
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138255
[No Abstract] [Full Text] [Related]
14. Multiple Primary Melanoma Associated with CDKN2A Mutation-Case Report and Review of the Literature.
Nurla LA; Aşchie M; Cozaru GC; Boșoteanu M
Medicina (Kaunas); 2024 May; 60(5):. PubMed ID: 38792946
[TBL] [Abstract][Full Text] [Related]
15. Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in
Astiazaran-Symonds E; Graham C; Kim J; Tucker MA; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Sampson JN; Zhu B; Bruno W; Queirolo P; Fornarini G; Sciallero S; Carter B; Hicks B; Hutchinson A; Jones K; Stewart DR; Chanock SJ; Freedman ND; Landi MT; Höiom V; Puig S; Gruis N; Yang XR; Ghiorzo P; Goldstein AM
JCO Precis Oncol; 2022 Nov; 6():e2200145. PubMed ID: 36409970
[TBL] [Abstract][Full Text] [Related]
16. Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of
Pauley K; Khan A; Kohlmann W; Jeter J
Front Oncol; 2022; 12():837057. PubMed ID: 35372037
[TBL] [Abstract][Full Text] [Related]
17.
Danishevich A; Bilyalov A; Nikolaev S; Khalikov N; Isaeva D; Levina Y; Makarova M; Nemtsova M; Chernevskiy D; Sagaydak O; Baranova E; Vorontsova M; Byakhova M; Semenova A; Galkin V; Khatkov I; Gadzhieva S; Bodunova N
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137564
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom.
Harland M; Cust AE; Badenas C; Chang YM; Holland EA; Aguilera P; Aitken JF; Armstrong BK; Barrett JH; Carrera C; Chan M; Gascoyne J; Giles GG; Agha-Hamilton C; Hopper JL; Jenkins MA; Kanetsky PA; Kefford RF; Kolm I; Lowery J; Malvehy J; Ogbah Z; Puig-Butille JA; Orihuela-Segalés J; Randerson-Moor JA; Schmid H; Taylor CF; Whitaker L; Bishop DT; Mann GJ; Newton-Bishop JA; Puig S
Hered Cancer Clin Pract; 2014; 12(1):20. PubMed ID: 25780468
[TBL] [Abstract][Full Text] [Related]
19. Identification, genetic testing, and management of hereditary melanoma.
Leachman SA; Lucero OM; Sampson JE; Cassidy P; Bruno W; Queirolo P; Ghiorzo P
Cancer Metastasis Rev; 2017 Mar; 36(1):77-90. PubMed ID: 28283772
[TBL] [Abstract][Full Text] [Related]
20. Psychosocial issues of individuals undergoing surveillance for increased risk of melanoma and pancreatic cancer due to a germline CDKN2A variant: A focus group study.
Klatte DCF; Onnekink AM; Hinnen C; van Doorn R; Potjer TP; van Leerdam ME; Bleiker EMA
J Genet Couns; 2023 Oct; ():. PubMed ID: 37876362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
